Charles A. Rowland Jr.

Biography

Mr. Charles A. Rowland, Jr., also known as Charlie, CPA, MBA, served as the Chief Executive Officer of Aurinia Pharmaceuticals Inc. from April 11, 2016 to February 6, 2017 and served as its President until February 6,2017. Mr. Rowland served as the Chief Financial Officer and Vice President at ViroPharma Inc. from October 20, 2008 to January 24, 2014 and also served as its Interim Principal Accounting Officer from June 20, 2012 to August 2012. Mr. Rowland was responsible for all areas of finance and accounting, including financial reporting, tax, treasury and strategic financial planning at ViroPharma. Mr. Rowland has over 32 years of diversified experience across a broad field of financial areas. He has extensive financial and operational experience as a Chief Financial Executive and a Senior Member of industry-leading pharmaceutical management teams. He served as Chief Financial Officer and Senior Vice President of Valeant Pharmaceuticals International, Inc. from August 2004 to December 6, 2006. He served as the Chief Financial Officer, Executive Vice President and Treasurer of Endo International plc from December 6, 2006 to September 2, 2008 and also served as its Co-interim Chief Executive Officer. He served as Interim Co-Chief Executive Officer, Executive Vice President and Chief Financial Officer at Endo Pharmaceuticals Inc., where he served from December 2006 to September 2008. Mr. Rowland served as Chief Financial Officer and Senior Vice President of Actavis Mid-Atlantic, LLC. He was responsible for Finance, business direction and activities pertaining to Actavis's operations and administration. He served as the Chief Financial Officer and Senior Vice President of Biovail Corporation International from August 2004 to December 2006. Mr. Rowland joined Actavis in July 2004. He held finance and operational positions at Biovail Pharmaceuticals. He served as Chief Operating and Financial Officer of Breakaway Technologies, Inc. from 2001 to 2004. He served as Vice President of Finance & IT of Global Pharma Ops. He served for four years at Pharmacia Corporation, where he served as Vice President of Finance and Global Supply. He spent five years at Novartis Pharmaceuticals Corporation where he served a series of progressively senior positions, including Vice-President of Planning and Decision Support. Prior to 1993, he spent nine years at Bristol-Myers Squibb Company, where he served as Director of Finance. He began his career in 1980 at United Brands Inc. He is a Board Member of the Philadelphia chapter of Financial Executives International. He has been Independent Director of Blueprint Medicines Corporation since March 2015. He has been a Director at Viking Therapeutics, Inc. since July 6, 2017. He has been a Director of PsiOxus Therapeutics Limited since August 17, 2017. He has been Director of Nabriva Therapeutics plc since June 23, 2017. He has been member of the Supervisory Board of Nabriva AG since January 2015 and Nabriva Therapeutics AG since January 8, 2015. He served as Member of Supervisory Board at Nabriva Therapeutics plc since January 8, 2015. He served as a Director of BIND Therapeutics, Inc. (now DNIB Unwind, Inc.) since May 2014. He served as a Director of Aurinia Pharmaceuticals Inc. from July 29, 2014 to February 6, 2017. He served as a Director of Idenix Pharmaceuticals, Inc. from June 10, 2013 to August 5, 2014 and Vitae Pharmaceuticals, Inc. from September 3, 2014 to October 25, 2016. He is a Member of the American and Pennsylvania Institutes of Certified Public Accountants. He is a Strategic Consultant. Mr. Rowland is a Certified Public Accountant. He holds a Master of Business Administration degree in Finance from Rutgers University and Bachelor of Science/BA in Accounting from the Saint Joseph's University.

Research Interest

Bussiness and Management